Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

226 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Active, Not Recruiting

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

NCT04626518

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • University of California at San Francisco ( Site 3008) San Francisco, California, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 3011) New Haven, Connecticut, United States
  • University of Chicago ( Site 3013) Chicago, Illinois, United States
  • University of Iowa ( Site 3012) Iowa City, Iowa, United States
View all 51 locations
View Trial Details
Active, Not Recruiting

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

NCT04626479

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • University of California at San Francisco ( Site 1008) San Francisco, California, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 1011) New Haven, Connecticut, United States
  • University of Chicago ( Site 1013) Chicago, Illinois, United States
  • University of Iowa ( Site 1012) Iowa City, Iowa, United States
View all 55 locations
View Trial Details
Active, Not Recruiting

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918

Conditions
Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, +1 more
Locations
  • Moores Cancer Center ( Site 1885) La Jolla, California, United States
  • University of Southern California Norris Comprehensive Cancer Center ( Site 1850) Los Angeles, California, United States
  • Hoag Memoriall Hospital Presbyterian ( Site 2056) Newport Beach, California, United States
  • UC Davis Health System ( Site 1864) Sacramento, California, United States
View all 192 locations
View Trial Details
Active, Not Recruiting

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877

Conditions
Endometrial Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
Locations
  • University of Alabama - Birmingham ( Site 3061) Birmingham, Alabama, United States
  • University of South Alabama, Mitchell Cancer Institute ( Site 3058) Mobile, Alabama, United States
  • HonorHealth Research Institute - Biltmore ( Site 3043) Phoenix, Arizona, United States
  • Arizona Oncology Associates PC- HOPE ( Site 3049) Tucson, Arizona, United States
View all 231 locations
View Trial Details
Active, Not Recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358

Conditions
Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, +8 more
Locations
  • University of Alabama at Birmingham-Medicine ( Site 0065) Birmingham, Alabama, United States
  • Arizona Oncology Associates-Arizona Oncology ( Site 0049) Tucson, Arizona, United States
  • Pacific Cancer Care ( Site 0023) Monterey, California, United States
  • UCSF Medical Center at Mission Bay ( Site 0043) San Francisco, California, United States
View all 256 locations
View Trial Details
Active, Not Recruiting

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT05853367

Conditions
Advanced Solid Tumors, Metastatic Solid Tumors, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Northwestern Memorial Hospital ( Site 0002) Chicago, Illinois, United States
  • The University of Louisville, James Graham Brown Cancer Center ( Site 0004) Louisville, Kentucky, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) Hackensack, New Jersey, United States
  • Rutgers Cancer Institute of New Jersey ( Site 0005) New Brunswick, New Jersey, United States
View all 25 locations
View Trial Details
Active, Not Recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147

Conditions
Adenocarcinoma Of Esophagus, Digestive System Diseases, Digestive System Neoplasms, +13 more
Locations
  • Hospital de Gastroenterología Dr Bonorino Udaondo Buenos Aires, Argentina
  • Instituto de Investigaciones Metabólicas - IDIM Buenos Aires, Argentina
  • Hospital Italiano de Buenos Aires Buenos Aires, Argentina
  • Fundación Centro de Medicina Nuclear y Molecular ER Córdoba, Argentina
View all 227 locations
View Trial Details
Active, Not Recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
Locations
  • Mayo Clinic in Arizona - Phoenix ( Site 0043) Phoenix, Arizona, United States
  • St Joseph Heritage Healthcare-Oncology ( Site 0035) Fullerton, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0005) Los Angeles, California, United States
  • University of California San Francisco ( Site 0010) San Francisco, California, United States
View all 188 locations
View Trial Details
Active, Not Recruiting

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • Research Site Chicago, Illinois, United States
  • Research Site Rochester, Minnesota, United States
  • Research Site Fairfax, Virginia, United States
  • Research Site Melbourne, Australia
View all 40 locations
View Trial Details

Related conditions